Nxera Pharma Co Ltd - Company Profile
Powered by 
All the data and insights you need on Nxera Pharma Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Nxera Pharma Co Ltd Strategy Report
- Understand Nxera Pharma Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Nxera Pharma Co Ltd patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| WO2022189366A1 | Application | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR DEMENTIA | A61K31/445; A61K31/46; A61P25/28 | September 15, 2022 |
| EP4055016A1 | Application | GPR52-MODULATORVERBINDUNGEN | A61K31/444; A61K31/501; A61K31/55; A61P25/18; C07D471/04; C07D487/04; C07D498/04 | September 14, 2022 |
| EP4041388A1 | Application | PROSTAGLANDIN-EP4-REZEPTORANTAGONISTVERBINDUNGEN | A61K31/165; A61K31/36; A61K31/437; A61K31/4412; A61P1/00; A61P13/12; A61P15/00; A61P19/00; A61P19/02; A61P25/00; A61P25/06; A61P25/28; A61P3/10; A61P35/00; A61P9/10; C07B2200/07; C07C235/12; C07C235/14; C07C235/26; C07C255/54; C07C255/59; C07C2601/02; C07C2601/04; C07C311/33; C07C311/51; C07C317/22; C07C317/32; C07C381/00; C07D213/30; C07D213/64; C07D213/68; C07D257/04; C07D305/06; C07D317/46; C07D317/54; C07D471/04 | August 17, 2022 |
| US20220251110A1 | Application | CGRP ANTAGONIST COMPOUNDS | C07D498/22 | August 11, 2022 |
| KR1020220098156A | Application | GPR52 조절제 화합물 | A61K31/444; A61K31/501; A61K31/55; A61P25/18; C07D471/04; C07D487/04; C07D498/04 | July 11, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer